ProMetic Life Sciences Inc. (TSE:PLI)’s share price shot up 5% during trading on Thursday . The stock traded as high as C$1.49 and last traded at C$1.46. 735,900 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 1,076,740 shares. The stock had previously closed at C$1.39.

Several research firms recently commented on PLI. National Bank Financial upped their price target on shares of ProMetic Life Sciences from C$2.00 to C$2.50 in a research note on Wednesday, August 30th. Royal Bank Of Canada decreased their price target on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research note on Wednesday, August 16th. TD Securities decreased their price target on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research note on Wednesday, August 16th. Scotiabank decreased their price target on shares of ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research note on Friday, July 7th. Finally, Canaccord Genuity decreased their price target on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research note on Monday, June 19th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of C$3.60.

The firm’s market cap is $1.01 billion. The company’s 50-day moving average is $1.44 and its 200-day moving average is $1.91.

In related news, insider Bruce Pritchard sold 84,594 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of C$1.15, for a total value of C$97,283.10. Also, Director Dwun-Hou Chen sold 32,321 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of C$1.14, for a total value of C$36,845.94. Over the last 90 days, insiders purchased 91,250 shares of company stock worth $114,989 and sold 263,696 shares worth $339,918.

ILLEGAL ACTIVITY WARNING: “ProMetic Life Sciences Inc. (PLI) Shares Up 5%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/09/prometic-life-sciences-inc-pli-shares-up-5.html.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.